Metraipolis › archive › dc_5deee9bce4bd
Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic… — Europe PMC PMID:42098470
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42098470
- DOI
- 10.1007/s12272-[numero omesso]-y
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T16:03:16.593Z
- SHA-256 of the archived text
9741b67bcb22363ccd65d99b4d6f7634fa1d47f34424a9084e5f445896368223- Stable URL of this page
https://metraipolis.com/documento/dc_5deee9bce4bd
How to cite
Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic… — Europe PMC PMID:42098470 — Europe PMC (en), https://europepmc.org/article/MED/42098470 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5deee9bce4bd (Metraipolis archive dc_5deee9bce4bd, sha256 9741b67bcb22363ccd65d99b4d6f7634fa1d47f34424a9084e5f445896368223)
BibTeX
@misc{dc5deee9bce4bd,
title = {Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic… — Europe PMC PMID:42098470},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42098470},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5deee9bce4bd; sha256 9741b67bcb22363ccd65d99b4d6f7634fa1d47f34424a9084e5f445896368223},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42098470. Agents can read the archived copy with the MCP tool read_document.